Literature DB >> 17433261

Bone morphogenetic protein-7 and interferon-alpha synergistically suppress hepatitis C virus replicon.

Naoya Sakamoto1, Mika Yoshimura, Tomomi Kimura, Keisuke Toyama, Yuko Sekine-Osajima, Mamoru Watanabe, Masaaki Muramatsu.   

Abstract

Various cytokines contribute to control hepatitis C virus (HCV) viral replication. HCV subgenomic replicon systems have been developed, and cell-cycle-dependent replication has been reported. But the molecules involved in this processes is not totally elucidated. The aim of this study is to investigate the involvement of the bone morphogenetic protein (BMP)-7, a member of TGF-beta superfamily, to the in vitro HCV replication. BMP-7 dose-dependently suppressed the replication and protein expression from the HCV replicon in Huh7/Rep-Feo cells and was associated with cell-cycle arrest at the G1 phase. These results were consistent with the effect of TGF-beta in a previous study. Combination of BMP-7 and interferon-alpha showed a synergic decrease of HCV replication, and was more effective compared to the treatment with interferon-alpha alone. This synergistic effect was also present in HCV-JFH1 virus cell culture. While BMP-7 alone did not stimulate expression of the interferon-stimulated genes (ISGs), it augmented interferon-induced expression of the ISGs independently of the interferon-induced Jak/STAT pathway. Taken together, BMP-7 may constitute a novel molecule to suppress HCV replication.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17433261     DOI: 10.1016/j.bbrc.2007.03.167

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  9 in total

1.  Inhibitory effect of a triterpenoid compound, with or without alpha interferon, on hepatitis C virus infection.

Authors:  Takako Watanabe; Naoya Sakamoto; Mina Nakagawa; Sei Kakinuma; Yasuhiro Itsui; Yuki Nishimura-Sakurai; Mayumi Ueyama; Yusuke Funaoka; Akiko Kitazume; Sayuri Nitta; Kei Kiyohashi; Miyako Murakawa; Seishin Azuma; Kiichiro Tsuchiya; Shinya Oooka; Mamoru Watanabe
Journal:  Antimicrob Agents Chemother       Date:  2011-03-28       Impact factor: 5.191

2.  Identification of novel N-(morpholine-4-carbonyloxy) amidine compounds as potent inhibitors against hepatitis C virus replication.

Authors:  Akiko Kusano-Kitazume; Naoya Sakamoto; Yukiko Okuno; Yuko Sekine-Osajima; Mina Nakagawa; Sei Kakinuma; Kei Kiyohashi; Sayuri Nitta; Miyako Murakawa; Seishin Azuma; Yuki Nishimura-Sakurai; Masatoshi Hagiwara; Mamoru Watanabe
Journal:  Antimicrob Agents Chemother       Date:  2011-12-27       Impact factor: 5.191

3.  A complex signaling network involving protein kinase CK2 is required for hepatitis C virus core protein-mediated modulation of the iron-regulatory hepcidin gene expression.

Authors:  Pelagia Foka; Alexios Dimitriadis; Eleni Kyratzopoulou; Dionysios A Giannimaras; Stefania Sarno; George Simos; Urania Georgopoulou; Avgi Mamalaki
Journal:  Cell Mol Life Sci       Date:  2014-04-10       Impact factor: 9.261

4.  Comparison of HCV-associated gene expression and cell signaling pathways in cells with or without HCV replicon and in replicon-cured cells.

Authors:  Yuki Nishimura-Sakurai; Naoya Sakamoto; Kaoru Mogushi; Satoshi Nagaie; Mina Nakagawa; Yasuhiro Itsui; Megumi Tasaka-Fujita; Yuko Onuki-Karakama; Goki Suda; Kako Mishima; Machi Yamamoto; Mayumi Ueyama; Yusuke Funaoka; Takako Watanabe; Seishin Azuma; Yuko Sekine-Osajima; Sei Kakinuma; Kiichiro Tsuchiya; Nobuyuki Enomoto; Hiroshi Tanaka; Mamoru Watanabe
Journal:  J Gastroenterol       Date:  2009-12-12       Impact factor: 7.527

5.  MicroRNA-130a is up-regulated in mouse liver by iron deficiency and targets the bone morphogenetic protein (BMP) receptor ALK2 to attenuate BMP signaling and hepcidin transcription.

Authors:  Kimberly B Zumbrennen-Bullough; Qifang Wu; Amanda B Core; Susanna Canali; Wenjie Chen; Igor Theurl; Delphine Meynard; Jodie L Babitt
Journal:  J Biol Chem       Date:  2014-07-07       Impact factor: 5.157

6.  Inhibition of hepatitis C virus replication by a specific inhibitor of serine-arginine-rich protein kinase.

Authors:  Yuko Karakama; Naoya Sakamoto; Yasuhiro Itsui; Mina Nakagawa; Megumi Tasaka-Fujita; Yuki Nishimura-Sakurai; Sei Kakinuma; Masaya Oooka; Seishin Azuma; Kiichiro Tsuchiya; Hiroshi Onogi; Masatoshi Hagiwara; Mamoru Watanabe
Journal:  Antimicrob Agents Chemother       Date:  2010-05-24       Impact factor: 5.191

7.  Antiviral activity of bone morphogenetic proteins and activins.

Authors:  Lucy A Eddowes; Kinda Al-Hourani; Narayan Ramamurthy; Jamie Frankish; Hannah T Baddock; Cynthia Sandor; John D Ryan; Dahlene N Fusco; João Arezes; Eleni Giannoulatou; Sara Boninsegna; Stephane Chevaliez; Benjamin M J Owens; Chia Chi Sun; Paolo Fabris; Maria Teresa Giordani; Diego Martines; Slobodan Vukicevic; John Crowe; Herbert Y Lin; Jan Rehwinkel; Peter J McHugh; Marco Binder; Jodie L Babitt; Raymond T Chung; Matthew W Lawless; Andrew E Armitage; Caleb Webber; Paul Klenerman; Hal Drakesmith
Journal:  Nat Microbiol       Date:  2018-12-03       Impact factor: 17.745

8.  Dynamics of Transforming Growth Factor (TGF)-β Superfamily Cytokine Induction During HIV-1 Infection Are Distinct From Other Innate Cytokines.

Authors:  Matthew Dickinson; Anna E Kliszczak; Eleni Giannoulatou; Dimitra Peppa; Pierre Pellegrino; Ian Williams; Hal Drakesmith; Persephone Borrow
Journal:  Front Immunol       Date:  2020-11-24       Impact factor: 7.561

9.  Serum Markers of Epithelial Mesenchymal Transition as Predictors of HCV-induced Liver Fibrosis, Cirrhosis and Hepatocellular Carcinoma.

Authors:  Mona M Zoheiry; Shaimaa Aa Hasan; Eman El-Ahwany; Faten M Nagy; Hoda Abu Taleb; Mona Nosseir; Mona Magdy; Safa Meshaal; Mohamed Darwish El-Talkawy; Inas Raafat
Journal:  Electron Physician       Date:  2015-12-20
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.